Remy Bosselut, M.D., Ph.D.

Remy  Bosselut, M.D., Ph.D.
Senior Investigator

Our lab's focus is on the transcriptional control of CD4+ T cell development and function. We are specifically interested in the transcriptomic programs controlling the emergence of CD4+ lineage in the thymus and in the transcriptional control of CD4+ T cell responses to pathogens and tumors.

Areas of Expertise
1) T lymphocyte 2) T cell development 3) T cell effector differentiation 4) Transcription 5) Chromatin

Contact Info

Remy Bosselut, M.D., Ph.D.
Center for Cancer Research
National Cancer Institute
Building 37, Room 3032A
Bethesda, MD 20892-4259
Ph: 240-760-6866
bosselur@helix.nih.gov

We study the differentiation and function of T lymphocytes (T cells), and specifically of CD4+ helper T cells, which are essential for immune responses. CD4+ lymphopenia underlies infectious complications and death in HIV-induced immunodeficiency, and is a chief cause of morbidity and mortality after myeloablative cancer chemotherapy. In addition, CD4+ T cells are involved in tumor control and clinical studies have established their potential as anti-tumor agents. CD4+ T cells typically recognize peptide antigens bound to class II Major Histocompatibility Complex molecules (MHC-II). Together with CD8+ T cells, which recognize MHC-I bound antigens and differentiate into cytotoxic effectors, they form the bulk of T cell populations in lymphoid organs and tissues.

Current research focuses on three key areas.

1) CD4+ helper T cell development in the thymus. CD4+ T cells differentiate in the thymus from CD4+CD8+ “double-positive” thymocytes that have received positive selection signals from MHC-II-peptide antigens. We are investigating how the transcriptomic and epigenomic program characteristic of CD4+ T cells is established in these precursors. This includes studying the mechanisms of action of the zinc finger transcription factor Thpok, which is necessary for intrathymic CD4+ T cell development and for the continued integrity of mature CD4+ T cells. Additionally, we are using a combination of high-throughput gene expression analyses (including single-cell RNA sequencing) and genetic approaches to identify new transcription factors and signaling pathways involved in the emergence of the CD4+-specific transcriptome.

2) Transcriptional control of the “fitness” of CD4+ T cell responses. We recently found that the transcription factor Thpok is necessary for the emergence of memory CD4+ T cells during infection, and for their function during recall responses (Ciucci et al, Immunity, 2019). Our studies in this field integrate gene expression analyses and genetics (including Crispr-Cas9 genome editing) to decipher the transcriptional network that controls the functionality of CD4+ T cell responses in acute and chronic infection models.

3) CD4+ T cell responses to cancer. Even though most current tumor immunotherapy strategies rely on cytolytic CD8+ T cells, CD4+ T cells are attractive tools to treat cancer because of their diverse functions, including cytokine production (e.g., IFN-gamma), help to CD8+ T cells, or impact on blood vessel permeability and angiogenesis. However, subsets of CD4+ T cells, including regulatory T cells, can restrain anti-tumor immunity and promote tumor growth. We are developing experimental models to understand the function of CD4+ T cells in the tumor micro-environment and to design strategies to harness their anti-tumor potential.

Scientific Focus Areas:
Cell Biology, Developmental Biology, Immunology, Molecular Biology and Biochemistry
View Dr. Bosselut's PubMed Summary.

Selected Recent Publications

  1. Ciucci T, Vacchio MS, Gao Y, Tomassoni Ardori F, Candia J, Mehta M, Zhao Y, Tran B, Pepper M, Tessarollo L, McGavern DB, and Bosselut R.
    Immunity. 50: 91-105.e4, 2019. [ Journal Article ]
  2. Ciucci T, Vacchio MS, Bosselut R.
    Proc Natl Acad Sci U S A. 114: 13236-13241, 2017. [ Journal Article ]
  3. Carpenter AC, Wohlfert E, Chopp LB, Vacchio MS, Nie J, Zhao Y, Shetty J, Xiao Q, Deng C, Tran B, Cam M, Gaida MM, Belkaid Y, and Bosselut R.
    J Immunol. 199: 1716-1728, 2017. [ Journal Article ]
  4. Vacchio MS, and Bosselut R.
    J Immunol. 196: 4848-56, 2016. [ Journal Article ]
  5. Vacchio MS, Wang L, Bouladoux N, Carpenter AC, Xiong Y, Williams LC, Wohlfert E, Song KD, Belkaid Y, Love PE, Bosselut R.
    Nat Immunol. 15: 947-56, 2014.

Dr. Remy Bosselut trained at the Institut Curie in Paris, France. He earned his M.D. degree in 1992 from the Xavier Bichat School of Medicine and his Ph.D. degree in 1993 from the University Denis Diderot, both in Paris. Dr. Bosselut obtained postdoctoral training at the NCI Experimental Immunology Branch and joined the Laboratory of Immune Cell Biology in 2000.

Position Keywords Contact Name Contact E-mail Number of Positions
Postdoctoral Fellow - Tumor Immunology

Tumor Immunology 

Remy Bosselut

remy.bosselut@nih.gov

1
Name Position
Mariah Balmaceno-Criss BSc. Postbaccalaureate Fellow (CRTA)
Laura Chopp B.S. Predoctoral Fellow (Graduate Student)
Thomas Ciucci Ph.D. Postdoctoral Fellow (Visiting)
Yayi Gao Ph.D. Postdoctoral Fellow (Visiting)
Smriti Kanangat Postbaccalaureate Fellow (CRTA)
Assaf Magen BSc. Predoctoral Visiting Fellow (Graduate Student)
Jia Nie Ph.D. Postdoctoral Fellow (Visiting)
Melanie Vacchio Ph.D. Senior Research Assistant
Qi Xiao Research Biologist